The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Sponsor

China-Japan Friendship Hospital (Other)

Overall Status

Completed

CT.gov ID

NCT01342614

Collaborator

(none)

140

Enrollment

Arms

Duration (Months)

Study Details

Study Description

Brief Summary

The objective of this study is to investigate the effect of metformin on the correlation between hyperinsulinemia and hypertension.

Condition or Disease	Intervention/Treatment	Phase
Diabetes Mellitus Essential Hypertension	Drug: Fosinopril Drug: Metformin	N/A

Study Design

Study Type:

Interventional

Actual Enrollment :

140 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

The Effect of Metformin on the Correlation Between Hyperinsulinemia and Hypertension

Study Start Date :

May 1, 2006

Actual Primary Completion Date :

Aug 1, 2009

Actual Study Completion Date :

Aug 1, 2009

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Fosinopril group Fosinopril group received fosinopril, 10mg, once per day.	Drug: Fosinopril Fosinopril group received fosinopril, 10mg, once per day.
Experimental: Metformin group Metformin group was treated with metformin hydrochloride, 500mg, three times per day	Drug: Metformin Metformin group was treated with metformin hydrochloride, 500mg, three times per day

Arm

Intervention/Treatment

Active Comparator: Fosinopril group

Fosinopril group received fosinopril, 10mg, once per day.

Drug: Fosinopril

Fosinopril group received fosinopril, 10mg, once per day.

Experimental: Metformin group

Metformin group was treated with metformin hydrochloride, 500mg, three times per day

Drug: Metformin

Metformin group was treated with metformin hydrochloride, 500mg, three times per day

Outcome Measures

Primary Outcome Measures

Blood pressure measurement [8 weeks]

Eligibility Criteria

Criteria

Ages Eligible for Study:

20 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

20 to 65 years of age, regardless of sex
duration of hypertension was <5 years
overweight or obesity, mild to moderate hypertension, receive no euglycemic agent or antiobesity drug